Skip to main content
. 2023 Jan 10;7(11):2364–2374. doi: 10.1182/bloodadvances.2022008854

Figure 2.

Figure 2.

TIM-3 expression in patients treated with imatinib, nilotinib, or dasatinib. There was no significant difference in the expression of TIM-3 among patients treated with imatinib, nilotinib, or dasatinib in T cells, CD4+T-cells, CD8+ T cells, T-regs or NK cells either as a proportion of T cells (A,C,E,G,I respectively) or absolute counts (B,D,F,H,J respectively). The Kruskal-Wallis test was used to compare groups; alpha was set at 0.05 (adjusted for multiple comparisons).